369 related articles for article (PubMed ID: 18924086)
21. Antimicrobials as potential adjunctive agents in the treatment of biofilm infection with Staphylococcus epidermidis.
Peck KR; Kim SW; Jung SI; Kim YS; Oh WS; Lee JY; Jin JH; Kim S; Song JH; Kobayashi H
Chemotherapy; 2003 Jul; 49(4):189-93. PubMed ID: 12886054
[TBL] [Abstract][Full Text] [Related]
22. In vitro development of resistance to DX-619 and other quinolones in enterococci.
Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
[TBL] [Abstract][Full Text] [Related]
23. Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection.
Oliveira AD; Höfling-Lima AL; Belfort R; Gayoso Mde F; Francisco W
Arq Bras Oftalmol; 2007; 70(2):286-9. PubMed ID: 17589701
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections.
Molina-Manso D; del Prado G; Ortiz-Pérez A; Manrubia-Cobo M; Gómez-Barrena E; Cordero-Ampuero J; Esteban J
Int J Antimicrob Agents; 2013 Jun; 41(6):521-3. PubMed ID: 23611308
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm.
Szczuka E; Kaznowski A
Folia Microbiol (Praha); 2014 Jul; 59(4):283-8. PubMed ID: 24390796
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
[TBL] [Abstract][Full Text] [Related]
27. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections.
Saginur R; Stdenis M; Ferris W; Aaron SD; Chan F; Lee C; Ramotar K
Antimicrob Agents Chemother; 2006 Jan; 50(1):55-61. PubMed ID: 16377667
[TBL] [Abstract][Full Text] [Related]
28. Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Jhanji V; Sharma N; Satpathy G; Titiyal J
J Cataract Refract Surg; 2007 Aug; 33(8):1488-9. PubMed ID: 17662450
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
30. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
31. Formation and properties of in vitro biofilms of ica-negative Staphylococcus epidermidis clinical isolates.
Qin Z; Yang X; Yang L; Jiang J; Ou Y; Molin S; Qu D
J Med Microbiol; 2007 Jan; 56(Pt 1):83-93. PubMed ID: 17172522
[TBL] [Abstract][Full Text] [Related]
32. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
34. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
Barry AL; Pfaller MA; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
[TBL] [Abstract][Full Text] [Related]
35. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.
Tellis M; Joseph J; Khande H; Bhagwat S; Patel M
J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446
[TBL] [Abstract][Full Text] [Related]
36. Biofilm-based implant infections in orthopaedics.
Arciola CR; Campoccia D; Ehrlich GD; Montanaro L
Adv Exp Med Biol; 2015; 830():29-46. PubMed ID: 25366219
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
DiVincenzo CA; Shatzer KL; Venezio FR
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
[TBL] [Abstract][Full Text] [Related]
38. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
39. Foreign body infections due to Staphylococcus epidermidis.
Uçkay I; Pittet D; Vaudaux P; Sax H; Lew D; Waldvogel F
Ann Med; 2009; 41(2):109-19. PubMed ID: 18720093
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of moxifloxacin versus vancomycin against biofilms of methicillin-resistant Staphylococcus aureus and epidermidis in an in vitro model.
Salem AH; Elkhatib WF; Ahmed GF; Noreddin AM
J Chemother; 2010 Aug; 22(4):238-42. PubMed ID: 20685626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
